Mortality News and Research

RSS

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

3 Sep 2025

Global mental health crisis demands urgent investment and action

More than 1 billion people are living with mental health disorders, according to new data released by the World Health Organization (WHO), with conditions such as anxiety and depression inflicting immense human and economic tolls.

2 Sep 2025

People live longer worldwide but not necessarily healthier, study finds

Researchers mapped the global healthspan-lifespan gap across 183 countries, showing people live longer but not healthier, with Africa experiencing the fastest widening gap. Distinct disease-burden clusters explain regional differences and highlight the need for region-specific health strategies.

2 Sep 2025

Cardiovascular screening in men aged 60 to 64 years does not reduce all-cause mortality

An invitation to attend a comprehensive screening examination for the early signs of cardiovascular disease (CVD) did not reduce all-cause death among men aged 60 to 64 years, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

2 Sep 2025

Prostate cancer rates rise as mortality decline slows in the United States

Today, the American Cancer Society (ACS) released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States.

2 Sep 2025

ESC and EAS release new dyslipidaemia guidelines

The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) have just published the new international recommendations for managing dyslipidaemias. They were presented at the Annual Cardiology Congress held in Madrid from August 29th to September 1st, 2025.

2 Sep 2025

Select groups of myocardial infarction patients benefit from Helicobacter pylori screening

Not all acute myocardial infarction patients should be offered routine screening for the stomach ulcer bacterium Helicobacter pylori.

1 Sep 2025

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Drug-coated devices not associated with improved outcomes in patients with peripheral artery disease

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients with myocardial infarction (MI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Tailored risk-based treatment does not improve outcomes in atrial fibrillation

An individually tailored multidimensional risk-based treatment strategy was not associated with improvements in clinical outcomes compared with usual guideline-based care in patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Research finds no added benefit from routine CT imaging after left main coronary intervention

Routine coronary computed tomography (CCT)-based follow-up after percutaneous coronary intervention (PCI) of the left main coronary artery did not reduce death, myocardial infarction (MI), unstable angina or stent thrombosis compared with symptom-based follow-up, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

ICD treatment does not lower death risk in patients with abnormal ECG after myocardial infarction

Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and abnormal ECG markers, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), according to a pooled analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

$Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction$

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of patients with MI and mildly reduced left ventricular ejection fraction (LVEF), according to an individual patient data meta-analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC/EAS Focused Update to Guidelines, about how best to manage lipid levels in patients to reduce cardiovascular risk, recommends the use of new cardiovascular risk predication algorithms. The update was published today at ESC Congress 2025.

30 Aug 2025

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

Updated ESC Guidelines, published today at ESC Congress 2025, put a focus on a woman's autonomy in making her own reproductive choices by promoting a transparent dialogue and shared decision-making for pregnancies that are high-risk for an adverse maternal and/or fetal event.

30 Aug 2025

REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks

Beta blockers-drugs commonly prescribed for a range of cardiac conditions, including heart attacks-provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function.

30 Aug 2025

Previous
1
...
63
64
65
66
67
68
69
...
1219
Next

Mortality News and Research

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Global mental health crisis demands urgent investment and action

People live longer worldwide but not necessarily healthier, study finds

Cardiovascular screening in men aged 60 to 64 years does not reduce all-cause mortality

Prostate cancer rates rise as mortality decline slows in the United States

ESC and EAS release new dyslipidaemia guidelines

Select groups of myocardial infarction patients benefit from Helicobacter pylori screening

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

Drug-coated devices not associated with improved outcomes in patients with peripheral artery disease

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Tailored risk-based treatment does not improve outcomes in atrial fibrillation

Research finds no added benefit from routine CT imaging after left main coronary intervention

ICD treatment does not lower death risk in patients with abnormal ECG after myocardial infarction

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News